Clinical Trials | September 01, 2022
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
The book “Science behind Suryanamaskar” has been compiled by the AIIA’s Department of Swasthavritta and Yoga.
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
Subscribe To Our Newsletter & Stay Updated
